Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for Miles D. White
+0.17 (0.34%)
Real-time:   12:07PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 48.59 - 48.92
52 week 39.28 - 49.43
Open 48.87
Vol / Avg. 1.13M/4.46M
Mkt cap 72.60B
P/E 36.53
Div/yield 0.24/1.97
EPS 1.33
Shares 1.49B
Beta 0.41
Inst. own 70%
Jul 14, 2015
Q2 2015 Abbott Laboratories Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Apr 24, 2015
Abbott Laboratories Annual Shareholders Meeting
Apr 22, 2015
Q1 2015 Abbott Laboratories Earnings Release
Apr 22, 2015
Q1 2015 Abbott Laboratories Earnings Call - Webcast
Mar 3, 2015
Abbott Laboratories at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 10.80% 8.50%
Operating margin 12.46% 12.75%
EBITD margin - 21.29%
Return on average assets 5.03% 4.09%
Return on average equity 9.78% 7.37%
Employees 77,000 -
CDP Score - 93 B


100 Abbott Park Rd
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Abbott Laboratories is engaged in the discovery, development, manufacture and sale of healthcare products. The Company’s business segments include established pharmaceutical products, which include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines; diagnostic products, which include a range of diagnostic systems and tests; nutritional products, which include a range of pediatric and adult nutritional products, and vascular products, which include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company is also engaged in the field of electrophysiology with technologies that can transform how physicians treat people with complex heart rhythm disorders.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Executive Vice President - Finance and Administration
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 50
Bio & Compensation  - Reuters
Stephen R. Fussell Executive Vice President - Human Resources
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard W. Ashley Executive Vice President - Corporate Development
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 50
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Ventures
Age: 53
Bio & Compensation  - Reuters
Heather L. Mason Executive Vice President, Nutritional Products, Global Commercial Operations.
Age: 54
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 52
Bio & Compensation  - Reuters
Jaime Contreras Senior Vice President - Core Laboratory Diagnostics, Commercial Operations
Age: 58
Bio & Compensation  - Reuters